ICON Public (NASDAQ:ICLR) Reaches New 52-Week Low – Should You Sell?

ICON Public Limited (NASDAQ:ICLR)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $150.91 and last traded at $153.62, with a volume of 819 shares traded. The stock had previously closed at $153.72.

Analyst Ratings Changes

Several research analysts recently commented on ICLR shares. JPMorgan Chase & Co. cut their price target on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Robert W. Baird cut their target price on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Barclays decreased their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research report on Friday, February 21st. Truist Financial lowered their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $265.82.

ICON Public Stock Down 0.8 %

The stock has a market capitalization of $12.32 billion, a P/E ratio of 15.97, a P/E/G ratio of 1.86 and a beta of 1.24. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. The stock’s 50 day simple moving average is $186.79 and its 200 day simple moving average is $216.96.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The business had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. As a group, research analysts predict that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Natixis Advisors LLC lifted its stake in ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after buying an additional 11,177 shares during the last quarter. State of Tennessee Department of Treasury increased its holdings in shares of ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock worth $33,333,000 after acquiring an additional 1,600 shares during the period. Kornitzer Capital Management Inc. KS lifted its position in ICON Public by 40.6% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock valued at $20,363,000 after purchasing an additional 28,050 shares during the last quarter. Motley Fool Wealth Management LLC boosted its stake in ICON Public by 2.3% during the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after purchasing an additional 1,466 shares during the period. Finally, Foyston Gordon & Payne Inc grew its position in ICON Public by 27.3% in the 4th quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock worth $10,845,000 after purchasing an additional 11,089 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.